statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Citigroup Inc. Acquires 50,869 Shares of ImmunoGen, Inc. (NASDAQ:IMGN)

Citigroup Inc. increased its holdings in ImmunoGen, Inc. (NASDAQ:IMGN  Free Report) by 26.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange...

Blair William & Co. IL Lowers Holdings in ImmunoGen, Inc. (NASDAQ:IMGN)

Blair William  Co. IL reduced its stake in shares of ImmunoGen, Inc. (NASDAQ:IMGN  Free Report) by 0.7% during the 3rd quarter, according to its most recent disclosure with the Securities...

Quantbot Technologies LP Sells 3,962 Shares of ImmunoGen, Inc. (NASDAQ:IMGN)

Quantbot Technologies LP cut its holdings in ImmunoGen, Inc. (NASDAQ:IMGN  Free Report) by 35.5% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 7,187 shares of the...

AbbVie completes the acquisition of ImmunoGen

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

AbbVie Completes Acquisition of ImmunoGen

AbbVie Completes Acquisition of ImmunoGen AbbVie Completes Acquisition of ImmunoGen PR Newswire NORTH CHICAGO, Ill., Feb. 12, 2024 Adds flagship antibody-drug conjugate (ADC) ELAHERE (mirvetuximab...

Barclays Keeps Their Hold Rating on ImmunoGen (IMGN)

In a report released on February 9, Peter Lawson from Barclays maintained a Hold rating on ImmunoGen (IMGN Research Report), with a price target...

ImmunoGen, Inc. (NASDAQ:IMGN) Has Found A Path To Profitability

We feel now is a pretty good time to analyse ImmunoGen, Inc.'s ( NASDAQ:IMGN ) business as it appears the company may...

ImmunoGen (IMGN, $29.55) Aroon Indicator entered a Downtrend on February 07, 2024.

For the last three days, A.I.dvisor has detected that IMGN's AroonDown red line is above 70 while the AroonUp green line is below 30 for three straight days. This move could indicate a strong...

ImmunoGen (NASDAQ:IMGN) Now Covered by StockNews.com

Research analysts at StockNews.com assumed coverage on shares of ImmunoGen (NASDAQ:IMGN  Get Free Report) in a research note issued on Tuesday. The firm set a hold rating on the...

ImmunoGen (IMGN, $29.26) price may climb as it broke lower Bollinger Band on Feb 02, 2024

This price move could be a signal that IMGN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options...

ImmunoGen, Inc. engages in the discovery and development of antibody-drug conjugates to improve outcomes for cancer patients. Its pipeline includes Mirvetuximab Soravtansine, IMGN632, IMGC936, and IMGN151. The company was founded on March 27, 1981 and is headquartered in Waltham, MA.

Volume	48.61M
52-Wk High	$31.25
52-Wk Low	$3.61

IMGN Immunogen, Inc.

About

Feed

News

Earnings

Fundamentals